Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development

Rhea-AI Impact

(High)

Rhea-AI Sentiment

(Very Positive)

Rhea-AI Summary

Biodesix (Nasdaq: BDSX) will present seven abstracts, including two oral sessions, at the AACR Annual Meeting in San Diego from April 17–22, 2026. Presentations cover blood- and tissue-based testing, tumor and immune profiling, a validated myeloid NGS panel, and multi-omic MRD pipeline development.

Highlighted technologies include mass spectrometry, Bio-Rad ddPCR, Thermo Fisher Ion AmpliSeq and Ion Torrent Genexus workflows, with partners Thermo Fisher, Bio-Rad and Memorial Sloan Kettering co-presenting MRD data.

AI-generated analysis. Not financial advice.

News Market Reaction – BDSX

+1.92%

4 alerts

+1.92% News Effect

-9.7% Trough Tracked

+$3M Valuation Impact

$157.73M Market Cap

0.5x Rel. Volume

On the day this news was published, BDSX gained 1.92%, reflecting a mild positive market reaction. Argus tracked a trough of -9.7% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $157.73M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

AACR abstracts: 7 abstracts Oral sessions: 2 oral sessions AACR dates: April 17–22, 2026 +5 more

8 metrics

AACR abstracts 7 abstracts AACR Annual Meeting 2026 presentations

Oral sessions 2 oral sessions AACR 2026 Biodesix presentations

AACR dates April 17–22, 2026 AACR Annual Meeting in San Diego

NGS turnaround 24 hours Ion Torrent Genexus NGS workflow result time

Poster ID 3743 ddPLEX EGFR/KRAS/BRAF NSCLC biomarker detection

Poster ID 5437 Combined genomic and proteomic MRD application

Poster ID 7828 Tumor-informed ctDNA MRD workflow development

Oral session time 3PM–5PM PST NSCLC variant-level frequencies oral presentation

Market Reality Check

Price: $14.89 Vol: Volume 40,523 is below th...

low vol

$14.89 Last Close

Volume Volume 40,523 is below the 20-day average of 104,389, suggesting a modest reaction pre-AACR. low

Technical Price $15.07 is trading above the 200-day MA of $8.99, reflecting a pre-existing uptrend.

Peers on Argus

BDSX gained 2.1% while peers were mixed: XGN up 4.44%, PRE up 1.08%, BNR and MDX...

1 Up 1 Down

BDSX gained 2.1% while peers were mixed: XGN up 4.44%, PRE up 1.08%, BNR and MDXH down, FONR flat. Momentum scanner shows MDXH down over 5% and PRPO up over 5%, reinforcing a stock-specific move for BDSX.

Historical Context

5 past events · Latest: Mar 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 20	Clinical validation data	Positive	-8.7%	Largest lung nodule biomarker validation study supporting earlier lung cancer diagnosis.
Feb 26	Q4/FY2025 earnings	Positive	+7.8%	Strong Q4 results, 83% gross margin, first positive Adjusted EBITDA, and 2026 revenue guidance.
Feb 24	Investor conferences	Neutral	+2.0%	Participation in TD Cowen and Barclays healthcare conferences with webcast fireside chats.
Feb 12	Earnings date notice	Neutral	+4.7%	Announcement of Q4 and FY2025 earnings release timing and accompanying conference call.
Jan 12	Preliminary results	Positive	+48.0%	Preliminary Q4/FY2025 results above guidance with strong lung diagnostics and services revenue.

Pattern Detected

BDSX has reacted positively to financial and operational updates but showed a notable selloff after a major positive clinical validation, indicating occasional divergence on strong scientific news.

Recent Company History

Over the past months, Biodesix reported strong growth with $88.5M 2025 revenue, positive Q4 Adjusted EBITDA of $0.5M, and upbeat 2026 revenue guidance. Preliminary 2025 results on Jan 12 drove a 47.99% gain, and formal Q4/FY results on Feb 26 added another 7.81%. In contrast, a major lung nodule biomarker validation on Mar 20 coincided with an 8.74% decline. Today’s AACR-focused pipeline and MRD update extends that scientific narrative.

Market Pulse Summary

This announcement outlines Biodesix’s presence at AACR 2026, with 7 abstracts, including 2 oral pres...

Analysis

This announcement outlines Biodesix’s presence at AACR 2026, with 7 abstracts, including 2 oral presentations, spanning NSCLC profiling, proteomic biomarkers, and multi-omic MRD workflows with 24-hour NGS turnaround. In context of 2025 revenue of $88.5M and recent positive Adjusted EBITDA, the AACR content highlights breadth in liquid biopsy and MRD capabilities. Investors may watch for follow-on updates translating these data into commercial diagnostics or development services growth.

Key Terms

molecular residual disease (mrd), nsclc, droplet digital pcr, ddpcr, +4 more

8 terms

molecular residual disease (mrd) medical

"Another set of presentations highlights a novel, multi-omic approach to MRD monitoring."

Molecular residual disease (MRD) is the tiny number of cancer cells that remain in a patient after treatment, detected by highly sensitive genetic or molecular tests that can find one cancer cell among thousands or millions of normal cells. MRD matters to investors because it helps predict the chance of relapse and influences whether additional treatment is given; MRD signals are increasingly used as early clinical trial or regulatory endpoints, so positive or negative MRD results can materially affect the market value of diagnostics and therapies—similar to an early warning that shapes future decisions.

nsclc medical

"Real-world analysis of NSCLC* variant-level frequencies from liquid biopsy testing..."

NSCLC stands for non-small cell lung cancer, which is the most common type of lung cancer. It develops in the lungs and can spread to other parts of the body, making it serious but often treatable if caught early. Understanding NSCLC helps people recognize the importance of lung health and early detection.

droplet digital pcr technical

"ddPLEX EGFR/KRAS/BRAF: A highly multiplexed droplet digital PCR™ (ddPCR™) panel..."

Droplet digital PCR is a laboratory method that splits a DNA or RNA sample into thousands of tiny droplets and runs many parallel tests so you can count exactly how many droplets contain the target genetic material. Like checking which bulbs in a giant string are lit, it gives a precise, highly sensitive measure of low-level DNA/RNA signals. Investors care because this accuracy enables better diagnostics, patient monitoring, and drug development decisions, and it supports sales of specialized instruments, assays, and recurring consumables.

ddpcr technical

"ddPLEX EGFR/KRAS/BRAF: A highly multiplexed droplet digital PCR™ (ddPCR™) panel..."

Droplet digital PCR (ddPCR) is a laboratory method that counts copies of specific DNA or RNA by splitting a sample into thousands of tiny droplets and testing each one, producing a precise, direct count rather than an estimate. For investors, ddPCR matters because its high sensitivity and accuracy are used in diagnostics, monitoring treatment response, and validating therapies and tests—functions that can drive regulatory approvals, market demand, and revenue for companies in healthcare and biotech.

next-generation sequencing (ngs) technical

"The platform supports an automated clinical next-generation sequencing (NGS) workflow..."

A laboratory technique that reads the sequence of DNA or RNA by processing millions of fragments at once, like scanning many pages of a book simultaneously instead of one at a time. It matters to investors because it accelerates and lowers the cost of genetic testing, drug discovery and diagnostics, expanding markets for biotech, diagnostics equipment and data services and enabling products that can change clinical care and revenue streams.

ctdna medical

"Development of a comprehensive tumor-informed ctDNA workflow for ultrasensitive..."

Circulating tumor DNA (ctDNA) is tiny fragments of genetic material shed by cancer cells into the bloodstream, like breadcrumbs that can reveal a tumor’s presence and genetic makeup without needing a biopsy. For investors, ctDNA matters because tests and technologies that detect and analyze these fragments can speed diagnosis, track treatment response, and signal relapse, creating commercial opportunities in diagnostics, personalized therapies, and monitoring services.

liquid biopsy medical

"variant-level frequencies from liquid biopsy testing in diverse U.S. populations"

A liquid biopsy is a laboratory test that looks for tiny pieces of tumor or disease-related material — such as DNA, proteins, or cells — circulating in blood or other body fluids, allowing detection and monitoring without a surgical tissue sample. For investors, it matters because these tests can speed diagnosis, guide treatment choices, enable easier repeat testing, and create recurring revenue streams if adopted widely, affecting a medical company's growth and regulatory risk profile.

bioinformatics technical

"proteomic and genomic biomarkers as well as bioinformatics workflows central to the Biodesix MRD pipeline..."

The use of computer tools and data analysis to organize and interpret large biological datasets, such as DNA, protein or patient information. It matters to investors because it speeds up research, lowers development costs and helps identify promising drug targets, diagnostics or personalized treatments—think of it as using GPS and analytics to find the fastest, most reliable route through vast amounts of lab data.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

04/06/2026 - 11:43 AM

Includes novel proteomic and genomic approaches to oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing

LOUISVILLE, Colo., April 06, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that the company will present seven abstracts, including two oral sessions, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, from April 17 - 22, 2026. The presentations demonstrate Biodesix capabilities in blood- and tissue-based testing and monitoring across a range of applications.

“Biodesix expertise in test discovery and development, regulatory, reimbursement, and commercialization provides an exceptional level of service for our partners across a range of applications. The AACR presentations showcase basic research through clinical applications and pre-validated assays available for biopharma and life science partners, as well as advancements in our pipeline efforts. The data are reinforced by more than a decade of experience supporting the clinical development and commercialization of new diagnostics and therapeutics,” said Gary Pestano, PhD, Chief Scientific Officer, Biodesix.

“The depth of experience and success across the Biodesix team, spanning real-world clinical care and cutting-edge research, will be on full display at this year’s AACR. It is especially exciting to see our genomic and proteomic technologies, combined with advanced data informatics, translating into meaningful clinical impact in our pipeline product concepts while also fueling strong momentum in our Development Services business as we move into 2026,” said Scott Hutton, CEO, Biodesix.

Tumor & Immune Profiling Expertise

Biodesix oral and poster presentations highlight diverse technology platforms, rapid turn-around times for our clinical tests, and extensive capabilities in immune and tumor profiling using mass spectrometry, Bio-Rad Droplet Digital PCR™, and Thermo Fisher Ion AmpliSeq™ platforms. In addition, Biodesix has validated a new clinical myeloid panel on the Thermo Fisher Ion Torrent™ Genexus™ System. The platform supports an automated clinical next-generation sequencing (NGS) workflow and can deliver sequencing results in as little as 24 hours.

Sunday, April 19 | 3PM–5PM PST | Oral Presentation | Room 17, Mezzanine Level, Convention Center
Title: Real-world analysis of NSCLC* variant-level frequencies from liquid biopsy testing in diverse U.S. populations

Monday, April 20 | 2PM–5PM PST | Poster Section 41
Poster: 3743. ddPLEX EGFR/KRAS/BRAF: A highly multiplexed droplet digital PCR™ (ddPCR™) panel for ultra-sensitive NSCLC biomarker detection

Wednesday, April 22 | 9AM–12PM PST | Poster Section 39
Poster: Blood-based proteomic profiling reveals novel biomarkers of Neuroendocrine Prostate Cancer

Monday, April 20 | 2PM–5PM PST | Poster Section 44
Title: Performance validation of a next generation sequencing myeloid assay on an integrated nucleic acid purification and sequencing system

Molecular Residual Disease (MRD) Product Pipeline

Another set of presentations highlights a novel, multi-omic approach to MRD monitoring. Thermo Fisher Scientific, Bio-Rad Laboratories, and Memorial Sloan Kettering Cancer Center will co-present new data on proteomic and genomic biomarkers as well as bioinformatics workflows central to the Biodesix MRD pipeline tests.

Monday, April 20 | 12:30PM | Spotlight Theater B - Sails Pavilion - Conv Ctr
Title: Leveraging Droplet Digital PCR™* (ddPCR™) for MRD Detection and Monitoring in Solid Tumors and Heme Malignancies

Tuesday, April 21 | 2PM–5PM PST | Poster Section 1
Poster: 5437. Sensitive detection of rare cfDNA variants utilizing molecular technologies and a novel informatics platform: A combined genomic and proteomic MRD application.

Wednesday, April 22 | 9AM–12PM PST | Poster Section 45
Poster: 7828. Development of a comprehensive tumor-informed ctDNA workflow for ultrasensitive molecular residual disease (MRD) detection using diverse tumor profiling inputs

The full abstracts for Biodesix and a list of all abstracts being presented at the AACR Annual Meeting can be found here.

ddPCR™ technology is a trademark of Bio-Rad Laboratories, Inc.
Ion Torrent™ Genexus^® System and Ion AmpliSeq™ Platform are trademarks of Thermo Fisher Scientific.
NSCLC is the acronym for Non-Small Cell Lung Cancer.

About Biodesix:

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung^® Nodule Risk Assessment and IQLung^® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications
natalie.stdenis@biodesix.com
(720) 925-9285

Investors:
Chris Brinzey, Partner, ICR
chris.brinzey@icrhealthcare.com
(339) 970-2843

FAQ

What AACR 2026 presentations will Biodesix (BDSX) deliver and when?

Biodesix will present seven abstracts, including two oral sessions, at AACR April 17–22, 2026. According to Biodesix, sessions include oral and poster presentations on April 19, 20 and 22 covering NSCLC variant analysis, ddPLEX ddPCR panels, proteomic biomarkers, and MRD workflows.

Which technologies does Biodesix (BDSX) showcase at AACR 2026?

Biodesix highlights mass spectrometry, Bio-Rad ddPCR, Thermo Fisher Ion AmpliSeq and Ion Torrent Genexus systems. According to Biodesix, these platforms support tumor and immune profiling, automated NGS with 24-hour sequencing, and ultra-sensitive ddPCR applications.

What MRD developments will Biodesix (BDSX) present at AACR 2026?

Biodesix will present a multi-omic MRD approach combining proteomic and genomic biomarkers and informatics workflows. According to Biodesix, collaborators Thermo Fisher, Bio-Rad and Memorial Sloan Kettering co-present data central to its MRD pipeline tests.

What is the new myeloid NGS validation Biodesix (BDSX) announced for AACR?

Biodesix validated a clinical myeloid panel on the Thermo Fisher Ion Torrent Genexus system for automated NGS. According to Biodesix, the platform can deliver sequencing results in as little as 24 hours and integrates nucleic acid purification and sequencing.

How does the ddPLEX ddPCR panel featured by Biodesix (BDSX) aim to improve NSCLC detection?

The ddPLEX EGFR/KRAS/BRAF panel is a highly multiplexed ddPCR assay for ultra-sensitive NSCLC biomarker detection. According to Biodesix, the poster demonstrates the panel's high multiplexing and sensitivity for detecting clinically relevant variant biomarkers.

Where can investors find Biodesix (BDSX) AACR abstracts and what topics do they cover?

Full abstracts and the complete Biodesix AACR abstract list are available via the company’s disclosures. According to Biodesix, topics include NSCLC variant frequencies, proteomic biomarkers for neuroendocrine prostate cancer, NGS myeloid validation, and MRD detection workflows.